You are here
- Home
- Therapy Areas
- Neuroscience
A Multicenter, open-label study using the MIDAS questionnaire to assess the effect of using the HCPC guidelines for migraine management in primary care, including the use of Zomig-ZMT (Zolmitriptan) orally disintegrating tablets 5.0mg and Zomig nasal spray 5.0mg as indicated.
- Disease
- migraine
- Drug Name
- Zomig
- Generic Name
- zolmitriptan
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- IV
- Start Date
- Jul 13, 2004
- Study Name
- D1223C00002
- Study Id
- D1223C00002
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
